IT Infrastructure Service Specialist (Contract)

• Providing IT support for users as well as C- level individuals in the assigned sites.
• Assistance with conference room meeting support.
• Installing, configuring, and maintaining PCs, peripherals, and mobile devices.
• Following-up on client questions and problems (hardware and software) until resolved.
• Documenting issues and resolutions, producing reports when required.
• Providing administrative support for IT systems, including user role and access permissions
• Improving and maintaining customer satisfaction
• Interacting with external service providers for additional support
• Contributing to testing and system quality compliance.
• Following corporate policies and procedures.
• And other duties and responsibilities as assigned.

• Bachelor's Degree in the field of information technology, computer science, engineering or science is preferred
• Relevant certifications such as CCNA and A+ are preferred
• Minimally 3-5 years IT onsite support experience, preferably in pharmaceutical or life science industries
• Solid knowledge of Windows OS, MS Office, iOS
• Strong written and verbal communication skills this a must.
• Ability to work independently and solve problems based on guidelines and experience.
• Strong quality and customer service mindset.
• Ability and willingness to learn new technologies and skills.
• Knowledge of system and network administration, cloud based applications is a plus.
• Experience in Office 365, Excel macro, Linux and/or Windows Shell scripting is a plus.

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma. Legend Biotech is seeking an IT Infrastructure Service Specialist (Contract) as part of the IT team based in Raritan, NJ., Legend Biotech was founded as an early-stage cell therapy company in 2014. The company was the brainchild of visionary scientists who recognized that antibody-based therapeutics could potentially treat disease and possessed the backgrounds in immunology and gene editing to take the leap. For two years, Legend Biotech, then known as the "Legend Project," operated in a room the size of a freight elevator, with the goal of creating a cell therapy for multiple myeloma, a hematological cancer that often relapses and can become refractory. The team produced nanobodies for single-domain antibody drugs and ultimately extended the half-life of the nanobodies with proprietary technologies. In 2015, Legend's scientists focused on research for chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein, making the biotech one of the first companies in the world to engineer CAR-T cells for the BCMA protein. In 2016, investigator-initiated trials began in China. In 2017, data from the trials were presented at the American Society for Clinical Oncology (ASCO), which led to a partnership with biopharmaceutical company Janssen Biotech, Inc. to co-develop the anti-BCMA CAR-T, ciltacabtagene autoleucel (cilta-cel). Applications seeking approval of cilta-cel for the treatment of patients with RRMM are currently under regulatory review by several health authorities around the world. CARVYKTI (ciltacabtagene autoleucel) was approved by the U.S. Food and Drug Administration in February 2022 and received conditional marketing approval from the European Medicines Agency in May 2022. Today Legend Biotech is a global, commercial-stage company driven by a passion for patients. We continue to build our pipeline of cell therapy platforms, which includes CAR-T, CAR-NK, CAR-γδ T and non-gene-editing CAR technologies. Our goal is to bring hope and opportunity to patients and their families by continuing to explore unique technologies.